RTW Biotech Opportunities Ltd with additional investment in Umoja Biopharma
January 17, 2025RTW Biotech Opportunities Ltd, a London Stock Exchange-listed investment company has made an additional investment in the Series C financing round of Umoja Biopharma (“Umoja”), a clinical-stage biotechnology company aiming to develop in vivo cell therapies that improve the reach, effectiveness, and access of CAR T cell therapies in oncology and autoimmune treatments.
The Series C was oversubscribed and raised $100 million in proceeds which will be used to advance Umoja’s in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies.
The Company first invested in Umoja’s Series B round in June 2021.
Roderick Wong, Managing Partner and CIO at the Investment Manager said: “We are delighted to continue supporting Umoja in advancing their groundbreaking work on in vivo CAR T cell therapies. The potential to meaningfully impact on patients’ lives is significant, and we are excited for the multiple benefits that could result from this innovative and exciting pipeline of therapies.”
The proceeds from this financing will enable Umoja to advance its in vivo CAR T cell therapy pipeline, including its lead CD22 UB-VV400 program in multiple oncology and autoimmune clinical studies.
In conjunction with the Series C financing, Campbell Murray, M.D., a Senior Adviser at Double Point Ventures, will be a new Board member at Umoja’s Board of Directors.
Dr. Murray said: “It is an honor to co-lead this transformative investment round and to join Umoja’s Board of Directors. Umoja’s groundbreaking work on in vivo CAR T cell therapies represents a new frontier in oncology and autoimmune treatment. The company’s innovation and leadership team position them at the forefront of this field, with the potential to significantly impact patients’ lives. I look forward to collaborating with Umoja’s exceptional team, investor base, and Board to advance these pioneering programs through clinical development and beyond.”
Andrew Scharenberg, M.D., co-founder and Chief Executive Officer of Umoja Biopharma, said: “We are pleased to announce the closing of our Series C financing with tremendous support from both new and existing investors who recognize Umoja’s potential to develop the industry’s first in vivo CAR T cell generating therapies—all in the hopes of increasing effectiveness, reducing barriers, and expanding access to CAR T cell therapies.”